Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity
06 févr. 2024 09h56 HE
|
Hofseth Biocare ASA
HBC Immunology Inc. (70.6% owned by Hofseth BioCare ASA) reports today the successful completion of the first in vivo study within its prostate cancer development program. The study assessed whether...
Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
09 janv. 2024 06h44 HE
|
Hofseth Biocare ASA
Reference is made to the stock exchange announcement on 4 January 2024 regarding the conclusion of an extraordinary general meeting in Hofseth Biocare ASA ("HBC" or the "Company") whereby the general...
Hofseth Biocare ASA: EXTRAORDINARY GENERAL MEETING CONCLUDED
04 janv. 2024 08h02 HE
|
Hofseth Biocare ASA
Hofseth Biocare ASA ("HBC" or the "Company") has today, on 4 January 2024, completed an extraordinary general meeting. All items proposed on the agenda were adopted, including the share capital...
Hofseth Biocare ASA: EGM Notice Correction
15 déc. 2023 05h29 HE
|
Hofseth Biocare ASA
Reference is made to the stock exchange notice announced by Hofseth Biocare ASA ("HBC" or the "Company") on 14 December regarding the notice for an extraordinary general meeting to be held at the...
Hofseth Biocare ASA: Notice of an extraordinary general meeting
14 déc. 2023 07h28 HE
|
Hofseth Biocare ASA
Reference is made to the stock exchange notice announced by Hofseth Biocare ASA ("HBC" or the "Company") on 13 December regarding an investment of NOK 144 million from Hofseth International AS...
Hofseth Biocare ASA: SIGNIFICANT NEW INVESTMENT OF NOK 144 MILLION FROM HOFSETH INTERNATIONAL INTO HBC
13 déc. 2023 16h49 HE
|
Hofseth Biocare ASA
The board of directors (the “Board”) of Hofseth BioCare ASA ("HBC" or the "Company") has reached an agreement with Hofseth International AS (“Hofseth International”) whereby HBC will issue a new class...
Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING
27 nov. 2023 05h06 HE
|
Hofseth Biocare ASA
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Reference is made to the mandatory notification of trade by Hofseth...
Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE
27 nov. 2023 04h56 HE
|
Hofseth Biocare ASA
Hofseth International AS, a close associate of Board member Roger Hofseth, has today agreed to acquire 435,207 shares in Hofseth BioCare ASA (the "Company"). The shares are purchased at a price of NOK...
Hofseth Biocare ASA: THIRD QUARTER 2023 FINANCIAL REPORT
10 nov. 2023 02h00 HE
|
Hofseth Biocare ASA
The third quarter of 2023 shows a significant growth of forty percent in sales compared to the same period last year and the increase in margins in Q2 continues. Sales revenues ended at NOK 49.9m vs...
Hofseth Biocare ASA: SECOND QUARTER 2023 FINANCIAL REPORT
25 août 2023 02h00 HE
|
Hofseth Biocare ASA
The second quarter of 2023 shows a 100 % growth in sales compared to the same period last year and strong increase in margins. Sales revenues ended at NOK 52.9m vs NOK 25.8m last year. The underlying...